The $2–3B Peptide Marketplace: Washington Is Building the Channel the FDA Is Prosecuting, and Hims & Hers Owns the Toll Booth

The administration is running two tracks at once. One track prosecutes the research-chemical supply chain that sells unapproved peptides to consumers; the other builds a supervised channel that competes with it. The sequencing is the point: enforcement shrinks the gray supply and pushes demand toward anything licensable, and the interim policy is designed to catch that demand before it goes back underground.

Kennedy's framing was about safety rather than science: Americans are going to buy peptides anyway, so the state should decide where and under what inspection. Read as policy design, that points to a government-run storefront in the mold of TrumpRx, the direct-to-consumer drug site the White House launched in February 2026, with state pharmacy boards continuing to license the pharmacies that would supply it. A channel that demands factory inspections can exclude research-chemical vendors without a rule that says legal.

The toll booth is Hims & Hers. It is the listed company with the whole stack — 2.89 million subscribers, a cash-pay channel already carrying branded Wegovy and Ozempic at $149 to $499 a month under a March agreement with Novo Nordisk, and API validation and stability testing already under way at its Menlo Park facility. Reuters reported that a Hims & Hers executive expects the peptide business to generate more than $1 billion of revenue over the next five to ten years, which is the size of prize the policy would formalize.

Compounded GLP-1s were the segment that actually mattered for pricing, and they are not in this policy. FDA reaffirmed on April 1 that compounded GLP-1s must be essentially copies of approved products once shortages resolved, and it moved to remove semaglutide and tirzepatide from the 503B bulk list. The peptides in the interim frame are BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — recovery, sleep, skin and longevity compounds with no branded equivalent and no human safety data. Nothing here touches the Zepbound or Wegovy franchises.

Eli Lilly grew Q2 2026 revenue 48% to $23.0 billion, with Mounjaro at $9.94 billion and Zepbound at $4.93 billion, and lifted full-year guidance to $85–87 billion. Novo Nordisk posted 7% adjusted sales growth at constant exchange rates on GLP-1 volume in obesity care even as realised prices fell, having already seen US Operations adjusted sales fall 11% at constant exchange rates in the first quarter. The bear case for both is not this policy; it is what the policy demonstrates about method.

Hims & Hers enters this with the only listed compounding-plus-telehealth stack positioned to sell into it. What the October policy changes is legal cover rather than product development, which is why management can guide to peptides before year-end while still waiting on final FDA rulemaking for the panel's six peptides, and why it has already started validating APIs.

If the marketplace is built on factory inspections, the constraint moves from molecules to documented supply. Goldman Sachs models global peptide API demand at roughly 99,000 kg a year by 2030, with about 35,000 kg serving the US market as US GLP-1 sales reach $66 billion, and China already leading synthetic API supply. The listed capacity play is WuXi AppTec, whose peptides and oligonucleotides business grew revenue more than 44% in the first half of 2026.

The next 90 days have three checkpoints, and only one has a fixed date. Nov. 9 is the Hims & Hers print. The White House's review of RIN 0910-ZD94 has no published timetable, but any released text would settle the three open questions: which peptides qualify, what safeguards attach, and when discretion ends. The third checkpoint is state-level: boards license the pharmacies, so the channel's real throughput will be set by whichever states move first.